v3.21.2
Condensed Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash $ 44,845,950 $ 13,953,513
Grants receivable 217,482  
Prepaid research and development 264,381 774,356
Prepaid expenses and other current assets 541,388 54,837
Total assets 45,869,201 14,782,706
Current liabilities:    
Accounts payable 553,801 1,720,680
Accrued expenses and other current liabilities 1,905,010 632,934
Deferred revenue 0 2,325,741
Notes payable 248,911 42,534
Total 2,707,722 4,721,889
Notes payable, net of current portion 0 276,461
Total liabilities 2,707,722 4,998,350
Commitments and contingencies (see Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; 0 shares issued and outstanding at September 30, 2021 and December 31, 2020
Common stock, $0.001 par value; 100,000,000 and 30,000,000 shares authorized; 25,155,198 and 10,050,849 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively. 25,155 10,051
Additional paid-in capital 67,912,392 24,805,929
Accumulated deficit (24,776,068) (15,031,624)
Total 43,161,479 9,784,356
Total liabilities and stockholders' equity $ 45,869,201 $ 14,782,706

Source